RT Journal Article
SR Electronic
T1 Early genomic detection of SARS-CoV-2 P.1 variant in Northeast Brazil
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.02.25.21252490
DO 10.1101/2021.02.25.21252490
A1 Tosta, Stephane
A1 Giovanetti, Marta
A1 Brandão Nardy, Vanessa
A1 de Oliveira da Silva, Luciana Reboredo
A1 Gómez, Marcela Kelly Astete
A1 Lima, Jaqueline Gomes
A1 Cardoso, Cristiane Wanderley
A1 Silva, Tarcisio Oliveira
A1 São Pedro Leal de Souza, Marcia
A1 Dia, Pedro H. Presta
A1 Fonseca, Vagner
A1 Lourenço, José
A1 Alcantara, Luiz Carlos Junior
A1 Pereira, Felicidade
A1 Leal, Arabela
YR 2021
UL http://medrxiv.org/content/early/2021/03/01/2021.02.25.21252490.abstract
AB Tracking the spread of SARS-CoV-2 variants of concern is crucial to inform public health efforts and control the ongoing pandemic. Here, we report genetic evidence for circulation of the P.1 variant in Northeast Brazil. We advocate for increased active surveillance to ensure adequate control of this variant throughout the country.Article Summary Line Active genomic surveillance of SARS- CoV-2 suspected cases from recent travelers reveals the circulation of the P1 variant of concern in Bahia state, Northeast Brazil.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was financed by Laboratorio Central de Saude Publica da Bahia (LACEN BA) and Secretaria da Saude do Estado da Bahia (SESAB) and supported by Pan American Health Organization PAHO/WHO. We also thank Centro e Informacoes Estrategicas de Vigilancia em Saude (CIEVS) in the municipality of Salvador, Bahia. ST is supported by the Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brasil (CAPES), Finance Code 001. MG is supported by Fundacao de Amparo a Pesquisa do Estado do Rio de Janeiro (FAPERJ). JL is supported by a lectureship from the Department of Zoology, University of Oxford. We also would like to thank all the authors who have kindly deposited and shared genome data on GISAID. A table with genome sequence acknowledgments can be found in Supplementary Table 1.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This research was approved by the Ethics Review Committee of the Federal University of Minas Gerais (CEP/CAAE: 32912820.6.1001.5149 approval number).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesNewly generated SARS-CoV-2 sequences have been deposited in GISAID under accession numbers EPI_ISL_1067728 to EPI_ISL_1067738.